08:47 AM EDT, 10/27/2025 (MT Newswires) -- RAPT Therapeutics ( RAPT ) said Monday it initiated a phase 2b clinical trial to evaluate ozureprubart as a treatment for patients with Immunoglobulin E-mediated food allergies.

The biopharmaceutical company said the study will be conducted at approximately 30 sites in the US, Canada, and Australia.

The study will compare two dosing regimens of ozureprubart versus placebo, with the first part including approximately 100 participants with at least one food allergy who will be treated for 24 weeks, the company said. It also said the primary endpoint for the trial is the proportion of participants who achieve a prespecified target threshold at a double-blind, placebo-controlled, oral food challenge at week 24.